Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Author:
Publisher
Cureus, Inc.
Subject
Aerospace Engineering
Reference14 articles.
1. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann M;Cell,2020
2. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis;Lucas JM;Cancer Discov,2014
3. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients - the "Gabrin sign";Wambier CG;J Am Acad Dermatol,2020
4. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - a potential clue to the role of androgens in COVID-19 severity;Goren A;J Cosmet Dermatol,2020
5. Androgenetic alopecia in COVID- 19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign;Wambier CG;J Am Acad Dermatol,2020
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. From bench to bedside: potential of translational research in COVID-19 and beyond;Briefings in Functional Genomics;2023-11-20
2. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response;Proceedings of the National Academy of Sciences;2023-07-17
3. Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein;Experimental and Therapeutic Medicine;2023-06-29
4. Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial;BMC Pharmacology and Toxicology;2023-06-15
5. Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature;Journal of Clinical Laboratory Analysis;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3